Mirna Therapeutics, Inc. Presents Preclinical Data on Lead Product Candidate MRX34 at Keystone Conference  
1/23/2013 9:37:31 AM

AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA (miRNA) replacement therapies for cancer, announced that new preclinical data from its lead product candidate will be presented this week at the Keystone conference on Non-coding RNAs in Development and Cancer in Vancouver, Canada, January 20th – 25th.